Late Breaking Abstract - Additive effect of BI 1015550 and nintedanib in patients with IPF
L. Richeldi (Roma, Italy), A. Azuma (Tokyo, Japan), V. Cottin (Lyon, France), C. Hesslinger (Biberach, Germany), S. Stowasser (Ingelheim, Germany), C. Valenzuela (Madrid, Spain), M. Wijsenbeek (Rotterdam, Netherlands), D. Wachtlin (Ingelheim, Germany), D. Zoz (Ridgefield, United States), T. Maher (Los Angeles, United States)
Source: International Congress 2022 – What is hot in interstitial lung diseases
Session: What is hot in interstitial lung diseases
Session type: Oral Presentation
Number: 1396
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Richeldi (Roma, Italy), A. Azuma (Tokyo, Japan), V. Cottin (Lyon, France), C. Hesslinger (Biberach, Germany), S. Stowasser (Ingelheim, Germany), C. Valenzuela (Madrid, Spain), M. Wijsenbeek (Rotterdam, Netherlands), D. Wachtlin (Ingelheim, Germany), D. Zoz (Ridgefield, United States), T. Maher (Los Angeles, United States). Late Breaking Abstract - Additive effect of BI 1015550 and nintedanib in patients with IPF. 1396
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|